Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (Viking)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
